Hengrui Medicine gets clinical trial nod for MASH drug HRS9531

Jiangsu Hengrui Medicine Co., Ltd. announced today that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for HRS9531 injection. The drug is cleared to proceed with clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).

HRS9531 injection is a novel, globally patented dual agonist targeting the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). This dual action aims to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity. The company believes HRS9531 holds promise for MASH patients by reducing hepatic lipid accumulation, mitigating inflammation, and potentially ameliorating liver fibrosis.

Currently, there are no approved drugs for MASH globally. Jiangsu Hengrui Medicine has invested approximately yuan 51,854 million in the HRS9531 project to date. The company cautions investors about the inherent risks in drug development and will provide timely updates on the project's progress.